Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer to Receive 2.66 Billion Pounds From Haleon
Drug giant Pfizer sells $3.3 bln stake in Sensodyne-maker Haleon
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Pfizer Raises $3.2 Billion by Selling Part of Haleon Stake
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer to Receive 2.66 Billion Pounds From Haleon in Share Deal
Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical company sold 640 million ordinary shares in British consumer-healthcare business Haleon at 380 pence a share.
Drug giant Pfizer sells $3.3 billion stake in Sensodyne-maker Haleon
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.
Pfizer Sells $3.26B Stake in Haleon
Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With this transaction,
Pfizer cuts Haleon stake in $3.3B share sale
Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual divestment strategy. Read more here.
Pfizer to sell about $3.25 billion stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
Haleon buys back £230m of its shares as Pfizer sells down stake
Haleon said Pfizer's stake was expected to fall to 15 per cent from 22.6 per cent. Haleon shares fell 0.25 per cent or 1.00p to 391.90p, having risen around 15 per cent in the las
2d
Is Pfizer a Buy Right Now or a Value Trap?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
4d
on MSN
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...
FiercePharma
4d
Amid large cost-cutting drive, Pfizer plans manufacturing layoffs in Ireland
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
sicklecellanemianews
4d
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Medscape
5d
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
FiercePharma
4d
Pfizer gins up £2.4B after unloading hundreds of millions of Haleon shares
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
STAT
9d
Pfizer pulls sickle cell treatment Oxbryta off global markets
The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...
10d
Deaths lead Pfizer to pull sickle cell drug at center of $5 billion Bay Area buyout
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...
2d
Pfizer: Patent Fears Priced In
Pfizer's latest quarterly earnings showed first YoY revenue growth since FQ4 2022. Read why PFE is still a compelling ...
STAT
9d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Haleon
AI
Sensodyne
GlaxoSmithKline
Johnson & Johnson
Feedback